BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and antiviral properties. BlueSky uses these delNS- mediated properties for therapies against cancer and viral infectious diseases.


The high level of interferon induced by the delNS vector activates immunological defence reactions against cancer. It also stimulates the production of antiviral molecules:

Immunostimulation / Immunomodulation

– NK –

activates Natural Killer Cells

– CTL –

activates Cytotoxic T-Cells

– DC –

activates Dendritic Cells

– Treg –

inhibits Immunosuppressive Regulatory T-Cells

– ΜΦ –

activates Macrophage

Antiviral molecules / Inhibition of viral replication

– ISG15 –

Interferon stimulated gene 15

– OAS –

Oligoadenylate synthetase

– PKR –

Protein Kinase R

– Mx –

Interferon-induced GTP binding protein

BlueSky’s delNS technology makes tumours vulnerable to the immune system


The Viennese biotechnology company BlueSky Immunotherapies announces three great news:

1. Superior interim efficacy data for elimination of HPV infection and associated cervical neoplastic lesions.

2. Application for clinical trial to treat HPV-positive oropharyngeal head and neck cancer submitted.

3. Last patient for intramuscular treatment of HPV infection and associated cervical neoplastic lesions recruited.


Visible success thanks to viral vector platform delNS in modern cancer therapy

The Viennese biotechnology company BlueSky Immunotherapies GmbH (Ltd.) has achieved visible success with its viral vector platform delNS for the therapy of equine sarcoids in horses in cooperation with the oncology team of the University of Veterinary Medicine Vienna. Those significant results show the further possibilities in the development of innovative and easy-on-the-body cancer therapies in humans. Read in our online article what that means for the future of immunotherapy against infectious diseases and cancer, and what other advantages delNS vectors offer in cancer therapy.




Preclinical studies have proven that the immunostimulatory properties of the delNS-vector “delNS/E6E7” destroy tumours. The vector’s potential for fighting metastases has also been demonstrated in animal models. Moreover, we have shown that delNS/E6E7 eliminates aggressive and incurable papilloma virus induced tumours in horses. Based on these promising results, BlueSky is currently conducting a phase I clinical trial with delNS/E6E7 for tumour elimination and prevention of cervical carcinoma in humans. Subsequently, its efficacy against cervical lesions, cervical cancer as well as head and neck cancer will be assessed in phase II trials.


Interferon also activates endogenous antiviral molecules such as the so-called protein kinase K (PKR). Based on this observation, we have developed “Pekarin”. As a first application, we have successfully tested Pekarin in animal models against influenza viruses. It was found that severity and duration of influenza were both significantly reduced. In principle, Pekarin can be used to fight all viruses. Accordingly, we recently demonstrated its efficacy in the mouse model against COVID-19.


Thomas Muster

– CEO –

Over 20 years biotech experience; more than 50 publications; 30 patents; has developed vaccines licensed to Baxter and Boehringer

● Vivaldi Biosciences
● AVIR Green Hills Biotechnology
● Mount Sinai School of Medicine

Michael Tscheppe

– CFO –

Over 20 years in finance, business administration & marketing; university lecturer

● Nuvonis Technologies
● AVIR Green Hills Biotechnology
● University of Applied Sciences
● Post AG

Christina Nicolodi

– Chief Regulatory Officer –

Christina Nicolodi
Senior regulatory affairs professional, global regulatory affairs, clinical development, clinical trial applications, marketing authorisations

● Takeda
● Shire
● Baxter

Markus Wolschek

– CSO –

Lead scientist; virology, genetic-engineering and product development expert, more than 30 publications and several patents

● AVIR Green Hills Biotechnology
● Medical University Vienna


Rüdiger Herrmann

– Squire Patton Boggs –

Noel Barrett

– CEO Affiris –

Josef Poandl

– Investor –


BlueSky’s delNS technology makes tumours vulnerable to the immune system

BlueSky Immunotherapies announced that its Clinical Trial Application for a phase 1 clinical trial of FLUBHPVE6E7, a delNS-based immunotherapy for the treatment of human papillomavirus-associated oropharyngeal cancer, has been formally accepted and is under review by the Austrian Agency for Health and Food Safety.

Equine sarcoids: visible sucess with delNS-based immunotherapy

Cancer therapy has reached a new milestone: BlueSky Immunotherapies has achieved to completely and permanently eliminate sarcoids in horses with its viral vector platform delNS and also the papillomvirus that causes this aggressive form of skin cancer.

Patent protection for innovative technology-platform

BlueSky Immunotherapies has secured its patents that cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein.



Thank you for visiting us. Please keep an eye on our site as we will add new content very soon. In the meantime, let’s stay in touch. If you have any question, query or idea, please send us an email.




    I agree that my data will be transmitted and processed in the course of this request.

    We are looking forward to connecting with our business partners.
    BlueSky Immunotherapies